Synthesis and secretion of Alzheimer amyloid βA4 precursor protein by stimulated human peripheral blood leucocytes  by Mönning, Ursula et al.
Volume 277, number 1,2, 261-266 FEBS 09285 December 1990 
Synthesis and secretion of Alzheimer amyloid PA4 precursor protein by 
stimulated human peripheral blood leucocytes 
Ursula Miinning’, Gerhard Kiinigr , Reinhard Prior’, Hans Mechler’, Ursula Schreiter-Gasse?, 
Colin L. Masters3 and Konrad Beyreutheri 
‘Center for Molecular Biology, University of Heidelberg, Im Neuenheimer Feld 282, D-6900 Heidelberg, Germany, 2 Central Institute 
for Mental Health, J 5, D-6800 Mannheim, Germany and 3Department of Pathology, University of Melbourne. Parkville, 
Victoria 3052, Australia 
Received 12 November 1990 
Alzheimer amyloid precursor proteins (APP) are actively secreted by stimulated human peripheral mononuclear blood leucocytes (PMBLs). Induc- 
tion of APP transcription, translation and secretion was observed with several T cell mitogens but was highest with phytohemagglutinin. The time 
course of induction is similar to that reported for IL-2 and IL-2 receptor. We suggest hat APP may play an important role in the construction 
of the immunological network and the differentiation of T cells. 
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1. INTRODUCTION 
Alzheimer’s disease is characterized by the presence 
of intra- and extraneuronal amyloid protein depositions 
in the brain of affected individuals. Amyloid appears as 
neurofibrillary tangles, amyloid plaques and vascular 
amyloid [l-4]. The amyloid PA4 protein is a small self- 
aggregating protein of about 42/43 residues that is syn- 
thesized as part of a larger, glycosylated transmem- 
brane amyloid precursor protein (APP) [1,3,5]. 
Transmembrane APP’s constitute a family of proteins 
that are generated from alternatively spliced transcripts 
(695, 714, 751 or 770 amino acids) of the single APP 
gene [5-g]. Proteolytic cleavage within the PA4 se- 
quence dissects the extracellular domains of APP from 
the transmembrane and cytoplasmic domain, and leads 
to secretion of C-terminally truncated, non- 
amyloidogenic proteins [lo,1 I]. The secreted forms of 
APP75r and APPv~, which contain a 57-amino acid in- 
sert with homology to the Kunitz family of protease in- 
hibitors, are protease nexin II [12,13]. Transmembrane 
as well as secretory APPs are found in brain and 
peripheral tissues, secretory APPs are also detected in 
body fluids such as blood and cerebrospinal fluid 
[14-201. 
activated platelets can secrete C-terminally truncated 
APP. Subsequently, it was shown that this APP is 
derived from APP751/77,,. The latter are natural in- 
hibitors of blood clotting factor XIa suggesting that 
these APP’s play an important role in blood coagula- 
tion [21-231. 
In this study we investigated another possible origin 
of APP in the serum. Here we demonstrate that 
peripheral mononuclear blood leucocytes (PMBL) 
secrete truncated APP, predominantly the variants con- 
taining the trypsin protease inhibitor domain 
(APP751,770), after stimulation by phytohemagglutinin 
(PHA), pokeweed mitogen (PWM) or concanavalin 
(ConA). It seems likely that APP is a T cell product 
since all three mitogens stimulate T cell proliferation 
and lymphokine production. The extensive expression 
of APP in stimulated PMBL’s indicates that the expres- 
sion of APP is correlated with certain stages of cell pro- 
liferation and cell differentiation. 
2. MATERIALS AND METHODS 
The identification of secreted APP in human sera 
from patients with Alzheimer’s disease as well as in sera 
of healthy individuals rises the question for the origin of 
APP in serum. Several authors could demonstrate that 
2.1. Cell preparation and culture conditions 
Human peripheral mononuclear blood leucocytes (PMBL) were ob- 
tained from buffy coats of normal donors (Blood Center, Heidelberg) 
by Ficoll-Hypaque gradient density centrifugation. The purification 
was performed essentially after Boyum et al. (1968) [25]. 
Isolated PMBLs or lymphocytes (monocyte-depleted PMBLs), 
were cultured at a density of 2 x lo6 cells/ml in Dulbecoo’s modified 
Eagle medium (DMEM, Gibco/BRL, UK) containing 1 g/l glucose, 
penicillin (50 U/ml), streptomycin (40 pg/ml), and 10% (v/v) fetal 
calf serum (FCS, Gibco/BRL, UK). 
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(10 pg/ml), concanavalin A (10 fig/ml) or pokeweed mitogen (5 
pg/ml) for different time intervals. Lectins were purchased from 
Sigma chemicals (St. Louis, MO, USA). Medium was not exchanged 
during stimulation. 
2.2. Biosynthetic labelling 
After removal of the culture medium by centrifugation, I x 10’ 
cells were radioactively labelled with 120 pCi of [3sS]methionine in 1.5 
ml of methionine-free DMEM. The conditioned medium was then 
cleared by centrifugation and stored at - 20°C. The cells were washed 
once with phosphate-buffered saline (PBS). For lysis, cells (5 x lo6 
cells) were resuspended in 0.2 ml lysis buffer [50 mM Tris (pH 7.5), 
150 mM NaCI, 2 mM EDTA, 1% Nonidet P40 supplemented with 2 
mM phenylmethylsulfonylfluoride (PMSF)] and incubated for 30 min 
on ice. Cell lysates were centrifuged at 10 000 x g for 5 min and the 
supernatants were stored at - 20°C until further use. The extraction 
pellet was discarded. 
2.3. Immunoprecipitation 
For immunoprecipitation, 100 ~1 of cell-lysate or 750 pl of condi- 
tioned medium were used. The cell-lysate was diluted 1:4 with ice- 
cooled PBS, the conditioned medium was supplemented with 15 pl 
medium buffer [l M Tris (pH 8.0), 100 mM EDTA, 10% Nonidet 
P40, 100 mM PMSF]. Lysate and medium were preincubated for 2 h 
at 4°C with 10 ~1 preimmune serum and 3 mg protein A-Sepharose 
(Pharmacia, Uppsala, Sweden). The insoluble complexes were spun 
down and discarded. The supernatants were incubated for 1 h at 4°C 
with 5 ~1 of undiluted anti-FdAPP antiserum. Anti-FdAPP is a 
polyclonal rabbit antiserum raised to purified E. coli FdAPP fusion- 
protein [14]. After addition of 2 mg of protein A-Sepharose the mix- 
ture was incubated for 30 min at 4°C. The insoluble complexes were 
washed three times with washing-buffer (20 mM Tris (pH 7.5), 150 
mM NaCl, 0.2% Nonidet P40,2 mM PMSF) and resuspended in 3 x 
Laemmli sample buffer. After boiling, labelled proteins were sub- 
jected to SDS-PAGE. Gels were soaked in En’Hance (New England 
Nuclear, USA), dried and exposed to Kodak X-Omat AR film for one 
week at -7O’C. 
2.4. Molecular cloning and Sl nuclease protection assay 
Molecular cloning and Sl nuclease protection assay were perform- 
ed as described by K&rig et al. [40]. 
2.5. Immunohistochemistry 
Cryosections (8 pm) were obtained from a muscle biopsy of a 
58-year-old female patient with polymyositis. Endogenous peroxidase 
was blocked with 1% Hz02 methanol for 30 min. Sections were then 
incubated overnight at room temperature with affinity purified 
monoclonal anti-APP antibody 22Cll at a concentration of 10 pg/ml 
[ 141. Bound antibody was detected using the avidin-biotin-peroxidase 
method (Vector, USA) and 3,3_diaminobenzidine as chromogenic 
substrate. The sections were counterstained with hematoxylin. An ir- 
relevant antibody was used as control. 
3. RESULTS 
Activated platelets are one possible origin of serum 
APP [21-231. Here we show that activated 
mononuclear blood leucocytes are another source of 
serum APP. To proof this, PMBLs were isolated from 
buffy coats of healthy donors and their APP expression 
was analysed. 
To assess the biosynthesis of APP by unstimulated 
PMBLs, freshly isolated cells were cultured without 
mitogens in the presence of [35S]methionine. The APP 
content of cell lysate and conditioned medium was 
analysed by immunoprecipitation. As shown in Fig. la, 
neither the culture medium nor the cell lysates contain 
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Fig. 1. Time course of APP biosynthesis in PMBLs after PHA induc- 
tion. Freshly isolated PMBLs were incubated in the absence (a) or in 
the presence of PHA (10 gg/ml) (b). Biosynthetic labelling with 
[35S]methionine was done at times indicated at the top of each lane. 
Cells and conditioned medium were subjected to immunoprecipita- 
tion with anti-FdAPP. The autoradiography of the im- 
munoprecipitates is shown (8% SDS-PAGE). 
APP. These data suggest that unstimulated PMBLs do 
not produce amyloid precursor proteins, or that they 
produce APP at such low levels that these are undetec- 
table in our assay system. 
Many genes of PMBLs are not constitutively express- 
ed, but can be induced by mitogens. In vivo, induced 
lymphocyte proliferation normally occurs outside of 
the blood and thoracic duct. In vitro, specific mitogens 
are able to trigger the conversion of resting lymphocytes 
into actively growing and dividing blasts [26]. Mitogen 
stimulation mimics the series of events which occur in 
vivo following stimulation of PMBLs by specific an- 
tigens. 
A very effective stimulator of T cell activation is the 
plant lectin phytohemagglutinin (PHA). The effect of 
PHA on the biosynthesis and secretion of APP was 
assessed after culturing PMBL’s for various times with 
PHA and [35S]methionine. Fig. lb clearly demonstrates 
that PHA strongly induces the production and secretion 
of APP. The addition of the T cell specific mitogen to 
the culture medium resulted in a rapid stimulation of 
APP biosynthesis. As shown in Fig. lb, anti-FdAPP 
antiserum could immunoprecipitate a 120 kDa protein 
from the culture medium. The band at 120 kDa has the 
same electrophoretic mobility as secreted APP in 
serum. APP secretion is observed within 3 h after PHA 
stimulation of PMBLs. Secretion continues over the 
whole stimulation period, i.e. over 4 days. In contrast, 
analysis of cell lysates showed that cellular APP was 
first detected 12 h after addition of PHA. The im- 
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Fig. 2. Immunoprecipitation of APP from [35S]methionine-labelled 
media of PMBLs stimulated with PHA, Con A, and PWM. Freshly 
isolated PMBLs were cultivated in the absence or in the presence of 
PHA, ConA or PWM. Biosynthetic labelling with [35S]methionine 
was performed after 2 days of cultivation. APP was isolated by im- 
munoprecipitation with anti-FdAPP antiserum. The im- 
munoprecipitates were analysed as in Fig. 2. 
munoprecipitates howed bands in the range of 90-130 
kDa which are molecular masses corresponding to in- 
termediates or final products of APP biosynthesis of 
transmembrane APP forms described by Weidemann et 
al. [14]. Accumultion of intracellular APP is therefore 
a late event; during the first 12 h the majority of APP 
is secreted. 
Initial experiments demonstrated that PMBLs could 
be triggered to secrete APP by stimulation with Con A, 
PWM and PHA. In addition, stimulation with PHA 
showed a 200 kDa band probably corresponding to an 
APP dimer since it is only seen if high concentrations of 
APP are present (Fig. 2). HPA seems to be the most po- 
tent inducer of APP biosynthesis. Because all three lec- 
tins stimulate T cell proliferation and lymphokine pro- 
duction and also trigger APP secretion of cultured 
PMBL’s, it seemed likely that APP is a T cell product. 
As shown in Fig. 3, stimulation of freshly prepared, 
monocyte-depleted PMBLs also resulted in secretion of 
APP. Adherence-selected monocytes failed to produce 
APP after treatment .with conditioned medium of 
PHA-stimulated PMBLs suggesting that APP secretion 
after PHA stimulation is indeed T cell specific. 
Preliminary results, however, suggest that monocytes 
also turn on APP biosynthesis during differentiation in- 
to macrophages. 
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Fig. 3. Secreted APP in PHA-stimulated monocyte-depleted PMBLs. 
Monocytes were cultivated for 2 days in the presence of 15 diluted 
conditioned medium of PMBLs after stimulation with PHA for 3 
days. Monocyte-depleted PMBLs were cultivated for 2 days with 
PHA. Biosynthetic labelling was initiated after the 2 day-period. APP 
of conditioned medium was analysed as in Fig. 2. The im- 
munoprecipitate from conditioned medium of lymphocytes is shown 
in lane 1 and of monocytes in lane 2. 
To confirm the presence of APP mRNA in activated 
T lymphocytes and to examine the time course of ex- 
pression of APP mRNA, human PMBLs were cultured 
with PHA for various periods of time. Total RNA from 
each group of cells was isolated and analyzed by a Sl 
nuclease protection assay [40]. Fig. 4a shows the induc- 
tion of APP mRNA in PBMLs at various times after 
stimulation. Unstimulated cells had low to undetectable 
levels of APP mRNA, while PHA-activated cells ex- 
pressed substantial levels of APP mRNA. The message 
appeared rapidly after stimulation. Elevations in the 
level of APP mRNA by a factor 16 are observed within 
2 h after exposure to PHA. Maximum levels of gene ex- 
pression (37-fold increase) are obtained within 24 h. 
After this time, the decrease of the APP message differs 
depending on cell preparation. In PHA-activated 
leucocytes the predominant APP gene splicing product 
is the APP~sI mRNA (Fig. 4b). The dominance of 
APP75r mRNA is even more significant during stimula- 
tion. The results of the mRNA analysis are in accor- 
dance with the protein data. APP transcription, 
translation as well as secretion correlate with stimula- 
tion of the PMBLs. 
An example for APP secretion by activated T lym- 
phocytes in vivo is given in polymyositis, an inflam- 
matory myopathy. This autoimmune disease is 
characterized by inflammatory and degenerative 
changes associated with endomysial infiltrates of 
cytotoxic lymphocytes. These infiltrates were strongly 
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Fig. 4. (a) Identification f APP transcripts in PMBLs by Sl nuclease 
protection assay. PMBLs were treated with PHA for 0 h (control, 
unstimulated PMBLs), 2 h, 12 h and 24 h. The corresponding 
fragments of APPw, APP~sI and APPvc, mRNAs are indicated by 
arrows. (b) Relative abundance of total APPxI and ratio of APP695 
to APP,5, to APP,,o. 
APP-positive when immunostained with the 
monoclonal anti-APP antibody 22Cll (Fig. 5). 
4. DISCUSSION 
We demonstrate for the first time that stimulated 
human mononuclear leucocytes produce APP and 
might be a source of circulating serum APP. In contrast 
to different cell lines that constitutively synthesize and 
secrete APP, secretion of APP was undetectable in 
resting PMBLs. We have demonstrated that the APP 
biosynthesis of human mononuclear blood leucocytes is 
highly increased following induction with the T cell 
specific mitogens phytohemagglutinin, concanavalin A 
or pokeweed mitogen. Of these, PHA has the most po- 
tent stimulatory activity. It seems likely that APP is a T 
cell product since all tested mitogens stimulate T cell 
proliferation and lymphokine production [27,28]. PHA 
activation resulted in a maximum 37-fold increase of 
APP mRNA levels and secretion of APP within 24 h. 
Resting T cells were found to have nearly undetectable 
levels of APP mRNA. Finally, APP appears to be pro- 
duced in vivo by cytotoxic lymphocytes which are a con- 
stant histological finding in muscle tissue of patients 
with polymyositis. Using immunohistochemistry with a 
monoclonal APP-antibody, we found strong im- 
munoreactivity in a majority of these muscle- 
infiltrating lymphocytes. 
The early APP gene response and the rapid secretion 
of APP at a time when cells are induced to proliferate 
may indicate a role of APP associated with T cell func- 
tion. In general, T cells mediate their responses both by 
cell/cell contact and by secreted lymphokines. This pro- 
cess is regulated in part via lymphokine feedback cir- 
cuits (for a review see [29]). The production of APP by 
T lymphocytes could therefore play a role in regulation 
of lymphocyte function or in the interaction of T cells 
with other cell types. The latter possibility is more likely 
since a general function of APP in cell/cell and 
cell/matrix interactions has been proposed for neuronal 
and non-neuronal APP [ 14,30-331. 
Freshly isolated human peripheral blood leucocytes 
are arrested in the G-phase of the cell cycle. Upon 
stimulation of resting lymphocytes, T cells enter the 
G-phase of the cell cycle. The physiological mechanism 
can be mimicked by mitogenic plant lectins such as 
PHA. Lymphocytes respond to it by the production of 
de novo gene transcripts, e.g. proto-oncogenes, 
transferrin receptor and critical components of T cell 
growth as interleukin 2 (IL-2) and IL-2 receptor [34,35]. 
The rapid induction of APP biosynthesis in response to 
a stimulus is comparable with the time course of IL-2 
induction [35]. This suggests that PHA stimulates lym- 
phocyte synthesis of APP by a mechanism similar to the 
one which regulates the synthesis of early-response gene 
products such as IL-2. Corresponding protein-binding 
regions are present in the promoter sequence of the 
APP gene as described by Salbaum et al. [36]. Among 
others, the APP promoter includes heptamer sequences 
which resemble the consensus binding site of the 
transcription factor AP-1. The products of the on- 
cogenes v-jun and c-fos have the ability to bind to this 
consensus sequence [37,38]. The actual control of 
transcription of the IL-2 gene appears to be regulated 
by a transcription enhancer in the 5 ’ -flanking region of 
the interleukin-2 gene. There are defined regions within 
this 5 ’ -flanking region to which particular nuclear fac- 
tors may bind in order to activate transcription. In- 
terestingly, the enhancer region of the IL-2 gene con- 
tains also an AP-1 binding site [39]. It has also been 
shown that the c-fos gene product is present in ap- 
propriately stimulated peripheral blood T cells [34]. 
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Fig. 5. APP expression in lymphocytes in vivo. Transverse section of a muscle biopsy obtained from a 58-year-old female patient with polymyositis. 
Atrophic and hypertrophic muscle fibers are seen, the endomysium is filled with lymphocytes that are strongly immunoreactive for APP. The 
periphery of some muscle fibers is invaded by cytotoxic APP-positive lymphocytes. Magnification x 200; counterstain with hematoxylin. 
The presence of activated AP-I has been suggested. 
Both the interleukin-2 gene and the APP gene are at- 
tractive candidates for c-fos or AP-I directed stimula- 
tion. 
Our results suggest that APP may play an important 
role in the construction of immunological networks and 
the differentiation of T cells. Thus, T cells may be an 
ideal model system to study the biological function of 
secretory APP. 
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